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Predicting the response of colorectal cancer (CRC) tumors to novel chemotherapeutic
agents is significantly complicated by their underlying genetic and epigenetic diversity.
Large-scale clinical trials involving thousands of patients are often necessary in order
to accurately determine efficacy during drug development. Recent advances in genetic
sequencing has allowed us to improve the prediction of drug response through genetic
stratification of patients into smaller populations, yet the complexity of the cancer genome
still often confounds accuracy of drug response prediction. Ultimately, we may need to
replicate patient’s own tumor in a dish in order to test drug responses so that the optimal
treatment can be identified. We recently developed highly efficient and tractable organoid
culture system for intestinal stem cells, in which single stem cells form 3D structures reca-
pitulating original tissue architecture. This technology has also been applied to colorectal
tumors and enables us to monitor the growth and response of the patient’s own tumors. In
this review, we provide an overview focusing on CRC organoid culture and its perspective
for clinical applications.
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INTRODUCTION
Colorectal cancer (CRC) is a major cause of cancer-related deaths
worldwide. In unresectable metastatic CRC patients, chemother-
apy may initially reduce tumor mass, although residual cancer cells
eventually cause relapse and death. Tumor recurrence is thought
to be caused by cancer stem cells (CSCs), a rare subpopulation of
cancer cells capable of self-renewal (1). Alternatively, rare cancer
cells may carry or subsequently acquire other mutations that allow
them to resist the treatment and form a more aggressive tumor. To
effectively prevent the expansion of drug-resistant tumor clones,
combinations of multiple chemotherapies with different spec-
trums of activity and toxicity have been used. The current standard
of treatment combinations has been determined through multiple
clinical controlled trials in order to provide the highest probability
of clinical response (2).
In contrast to conventional chemotherapy, which is cytotoxic to
all dividing cells including normal cells, more recent therapies have
been developed to specifically target the tumor. These targeted
therapies inhibit specific signal pathways aberrantly activated in
cancer cells and are typically effective in only a subset of tumors.
This subset may carry specific biological or molecular alterations
that can be predicted by biomarkers. The development of targeted
therapy has been changing which cancer therapy a patient receives
from a standardized “predetermined” approach to a more “per-
sonalized/tailored” approach. In CRC, the presence of oncogenic
mutations in KRAS was found to predict clinical response to anti-
EGFR therapy. Other genetic mutations in EGF signaling, such as
BRAF, PIK3CA, were also predictive of response (3). However, this
is not the case for all CRC patients, since a subset of tumors do
not respond as predicted, presumably because of the presence of
additional genetic alterations confounding genetic interactions.
Therefore, alongside genetic biomarkers, the development of a
biological platform based on cellular response to therapy is war-
ranted. Xenograft and primary culture of patient-derived cancer
cells represents two experimental models that can be used to
predict the drug response of individual patient tumors.
PATIENT-DERIVED XENOGRAFT
Patient-derived tumor xenograft (PDX) model was first reported
back in 1969 (4). Owing to a lack of efficient primary culture
methods the xenograft system has been preferentially used to
generate patient-derived tumor models. The use of immunode-
ficient mice as recipient animals and optimization of the tumor
implantation site (kidney capsule is superior to subcutaneous
injection) has achieved tumor take rates in the PDX model of
up to 90% (the take rate varies depending on reports and the
expected take rate is between 30 and 60%. Note that take rate is
higher in tumors from advanced stage) (5–13). The tumorigenic
potential of PDX has been shown to be conferred by a relatively
small population of CRC cells that are marked by stem cell mark-
ers for normal intestinal epithelium, such as CD133, CD44, or
LGR5 (leucine-rich repeat-containing G-coupled receptor 5) (7,
8, 14–16). Moreover, combined with culture system (described
later), it has been demonstrated that single CD133+ CSC form
tumors recapitulating histological traits of original tumor in PDX
mice, indicating robust clonal capacity in this model. Maintain-
ing actively growing PDX over time is achieved through “passage”
into other recipient mice, and across the world researchers use a
great number of animals, raising issues about cost-effectiveness,
scalability, and animal-welfare. Obtaining sufficient numbers of
PDX mice for drug screening can take more than half a year, dur-
ing which time the patient’s tumor might change their genetic
status and biological behavior, or deprive the patient of their life.
Therefore, although PDX is an attractive system for CRC drug
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development, the increasing need for personalized medicine will
necessitate a more rapid and tractable culture system in order to
model patients’ tumors.
SPHEROID CULTURE SYSTEM FOR COLORECTAL CANCER
Establishing a culture system to model patient-derived CRC has
been a research priority for many years, although until recently it
had only been met with limited success. Serum-based culture has
had some success in establishing a number of CRC cell lines over
the years, although these represent a rare group of tumors that
are able to adapt to the standard cell culture conditions (17). Var-
ious modifications have subsequently been made to improve the
number of tumors that can be cultured. This includes the use of
low-serum culture, supplementation of conditioned medium, use
of fibroblast feeder cultures, or collagen type I-coating substrate,
and take rates of up to 45% have been reported (18–21). However,
such protocols are often not reproducible in other labs, most likely
due to technical difficulty and low cloning efficiency. The diffi-
culty in culturing CRC may underlie insufficient maintenance of
CSC. Ricci-Vitiani et al. applied clonal neurosphere culture assay
to CRC cells, and showed that CD133+ CSCs successfully form
spheroid structures (8). The spheroid culture system was initially
developed for neural stem cells, in which stem cells are cultured on
a low attachment plate with serum-free medium containing EGF
and basic FGF (22). Spheroids from CD133+ CRC cells showed
long-term self-renewal and differentiate when placed in medium
with 5% serum instead of EGF and basic FGF (8). The CRC spher-
oid culture system has been reproduced in other labs, although the
reported culture efficiency is variable. Kondo et al. has established
another type of spheroid culture for CRC (23). In this culture sys-
tem, dissociated cell clusters from CRC tumors formed spheroid
structures termed “cancer tissue-originated spheroids” (CTOSs)
in modified ES culture medium. CTOSs were subsequently trans-
ferred into collagen type I-based extracellular matrix for long-term
culture. However, dissociated single cells failed to form CTOSs,
making it difficult to apply this system to clonal culture. In either
the CRC spheroid assay or CTOS culture, the success rate of long-
term culture for CRC was <50%, suggesting one or more factors
that are required to maintain CSCs are missing in these culture
conditions.
ORGANOID CULTURE TECHNOLOGY
As described earlier, several lines of evidence have suggested that
CSCs account for the indefinite expansion of CRC in vivo. The
mechanism underlying maintenance of CSCs in CRC remains
undetermined, but it is possible that they might use a similar stem
cell maintenance system as used by normal colon epithelium. This
notion is supported by our development of a culture condition
for normal intestinal stem cells (ISCs) and demonstration that it
can be successfully applied to CRC culture (24, 25). ISCs reside at
the bottom of intestinal crypts and are responsible for constant
production of rapidly self-renewing intestinal epithelium over an
individual’s lifetime. Intestinal crypts have been difficult to expand
in vitro over the decades, with the exception of embryonic intesti-
nal epithelium or SV40-immortalized epithelium, intestinal crypts
have proved difficult to expand in vitro (26, 27). Evans et al. first
reported primary adult intestinal crypt culture, in which intestinal
crypts attached to a collagen type I-coated dish propagated for up
to 2 weeks in vitro (28). Recently, we have developed organoid cul-
ture technology, in which mouse ISCs indefinitely propagate and
form stereotypic organoid structures in the presence of the basal
lamina mimetic, Matrigel (24) (Figure 1). The culture system was
developed based on biological properties of ISCs elucidated by
genetically engineered mice model. Firstly, in vivo crypt prolifer-
ation was shown to require either loss of Adenomatous Polyposis
Coli (APC) or activation of Wnt signaling through R-spondin
treatment (29, 30). Secondly, transgenic expression of bone mor-
phogenic protein (BMP) antagonist, noggin, ectopically generated
crypts in the surface of mucosa (31). Thirdly, EGF signal activation
was essential for intestinal epithelial self-renewal (32). From this
evidence, we found that three growth factors (Wnt/R-spondin,
EGF, and Noggin) are sufficient to allow self-renewal of mouse
ISCs. The established organoids can be passaged and indefinitely
cultured without signs of cellular senescence.
Human intestinal epithelium was found to be less well suited
to an in vitro environment and died within a week under the cul-
ture conditions optimized for mouse intestinal epithelium (25).
Two small molecule inhibitors, A83-01 (ALK-4/5/7 inhibitor)
and SB202190 (p38 inhibitor) drastically improved culture effi-
ciency and prolonged culture period up to at least 2 years without
noticeable transformation (25). These results additionally indi-
cated that normal ISCs can propagate over the Hayflick limit in
optimal culture condition, underscoring the importance of niche
microenvironments for long-term stem cell maintenance.
DEVELOPMENT OF ORGANOID CULTURE FOR COLORECTAL
CANCER CELLS
Intestinal organoid culture system has been applied to various
samples of digestive tissue epithelium and diseased epithelium,
including mouse intestinal adenoma and human CRC cells (25,
33). As Wnt signaling is aberrantly activated in mouse adenoma
and most of human CRC, organoids derived from tumor epithe-
lium readily proliferates independent of Wnt and R-spondin.
Presumably for similar reasons, CRC cells often grew with a fewer
number of niche factors compared with that of their normal coun-
terpart. Importantly, however, CRC cells often remain dependent
on some niche factors for normal ISCs, suggesting that these may
play a role in the maintenance of CSCs (Figure 1).
In CRC organoid culture condition, the success rate of estab-
lishing culture is superior to that of previously reported cul-
ture systems. Furthermore, single CRC cells are immobilized in
Matrigel and their clonal CRC organoids can be tracked on a real
time basis, which may enable visualization of self-renewal of CSCs
in a dish. Their clonal expansion capacity could be applied to var-
ious biomedical analyses including deep sequencing that would
normally require a microgram order of genomic DNA. Com-
bined with integrated molecular information, establishing “living
biobanks” would be a useful resource for both basic research and
clinical applications (Figure 2).
There are some drawbacks in CRC organoid culture. Organoids
are composed of pure epithelial cells, making it difficult to
assess the effect of treatment targeting non-epithelial cells, such
as endothelial cells or immune cells. Anti-VEGF therapy tar-
geting tumor vascularization has been used for CRC in clinic,
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FIGURE 1 | Organoid culture of normal and tumor epithelium.
Normal intestinal epithelial cells and colorectal cancer (CRC) cells are
isolated from intestine and cultured in Matrigel and optimal niche
factors. Normal epithelium consistently forms stereotypic organoid
structures resembling intestinal crypts, whereas CRC developed
dysplastic organoid structures.
FIGURE 2 | Application of CRC organoid technology. Patient-derived
CRC organoids are applied to basic and clinical research: deep sequencing
of pure epithelial cancer cells, drug development, prediction of clinical
responses in patients, and establishment of living biobanks.
although the assessment of this targeted therapy is difficult in CRC
organoids compared with the PDX model, in which mouse derived
endothelial cells migrate into xenografted CRC and form tumor
vasculature (34, 35). Although CRC organoids maintain glandu-
lar histologic structures and retain some differentiation capacity,
it remains unknown to what extent they could mimic the tumor in
the patient’s body. Further studies are needed to compare the pro-
file of gene expression between CRC organoids and their parental
tumor samples.
A striking advantage of CRC organoids is their expansion effi-
ciency, approximately 1000 times expansion per month, which
enables quick preparation of a large number of CRC cells in a short
time. This scalability and rapid expandability makes organoid cul-
ture suitable for drug testing and personalized medicine using
patient-derived cancer. Whilst it is not possible to perfectly reca-
pitulate patient-derived cancer in a certain experimental platform,
the best option at this stage is to use a combination of two compli-
mentary systems: PDX and CRC spheroids/organoids, depending
on applications.
In summary, the CRC organoid culture system provides a
tractable platform to mimic the patient’s CRC in vitro. It remains
unknown whether the drug responses in organoids in vitro can
predict their clinical response in patients, but if this is proven to
be the case, organoid technology might dramatically change the
current pipeline of drug discovery.
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